

Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

At Page 7, line 1:

Another embodiment of the invention includes monoclonal antibodies or a fragment, analogue or homologue thereof, or a peptide, oligonucleotide, peptidomimetic or an organic compound which bind to the same epitope as the antibody 175-62. These antibodies can include Fab, F(ab')₂, Fv or single chain Fv, and may be chimeric, DEIMMUNIZED™, humanized or human antibody. In addition, the present invention includes cell lines that produces the monoclonal antibody or fragment thereof that bind to the same epitope as the antibody 175-62.

At Page 10, line 14:

When treating inflammatory or autoimmune diseases in humans, the anti-C2a antibodies may be chimeric, DEIMMUNIZED™, humanized or human antibodies. Such antibodies can reduce immunogenicity, thereby avoiding a human/anti-mouse antibody (HAMA) response. It is preferable that the antibody be IgG4, IgG2, or other genetically mutated IgG or IgM which does not augment antibody-dependent cellular cytotoxicity (S.M. Canfield et al., *J. Exp. Med.*, 1991, 173: 1483-1491) and complement mediated cytotoxicity (Y.Xu et al., *J. Biol. Chem.*, 1994, 269: 3468-3474; V.L. Pulito et al., *J. Immunol.*, 1996, 156: 2840-2850).

At Page 11, line 12:

DEIMMUNIZED™ antibodies are antibodies in which the T-helper epitopes have been eliminated, as described in International Patent Application PCT/GB98/01473. They have either reduced or no immunogenicity when administered *in vivo*.

IN THE CLAIMS:

Please cancel claims 1-18 without prejudice or disclaimer to the subject matter contained therein.

Please add the following new claims:

- 19. (NEW) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits complement activation at a molar ratio of about 1:2 (antibody to C2).